Vaxcell-Bio Therapeutics Ordinary Shares 323990
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 18,890.00–19,800.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 19,120.00 / KRW 19,150.00
- Market Cap
- KRW 435.18 Bil
- Volume/Avg
- 237,915 / 356,063
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 53
- Website
- http://www.vaxcell-bio.com
Comparables
Valuation
|
Metric
|
323990
|
310210
|
052020
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.91 | 7.42 | 9.87 |
Price/Sales | — | 805.74 | 51.22 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
323990
|
310210
|
052020
|
|---|---|---|---|
Quick Ratio | — | — | — |
Current Ratio | 29.60 | 4.69 | 12.59 |
Interest Coverage | −260.75 | −18.54 | −270.58 |
Quick Ratio
323990
310210
052020
Profitability
|
Metric
|
323990
|
310210
|
052020
|
|---|---|---|---|
Return on Assets (Normalized) | −29.47% | −42.78% | −43.51% |
Return on Equity (Normalized) | −30.90% | −96.10% | −54.60% |
Return on Invested Capital (Normalized) | −33.70% | −44.97% | −54.02% |
Return on Assets
323990
310210
052020
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nlbfkrfq | Lync | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wqjzxqv | Mjsyvhy | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ksjrbdll | Dcqttxr | $108.2 Bil | |
MRNA
| Moderna Inc | Vdrqbxhg | Wpwz | $50.9 Bil | |
ARGX
| argenx SE ADR | Xjrmxhx | Xxjkw | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Rxtwfjpky | Cnfp | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jsqnwqzm | Bfpxz | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dyxdgjbry | Xklykp | $14.6 Bil | |
INCY
| Incyte Corp | Wlqsxpwvx | Shxkbn | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vfvfmwqrx | Qrmdrt | $12.3 Bil |